SUVEN PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of SUVEN PHARMACEUTICALS have increased by 1.52% YoY .
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -26.98 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
SUVEN PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 543064|NSE : SUVENPHAR]
| Consolidated | Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 |
|---|---|---|---|---|---|
| Revenues | ₹1,340 Cr | ₹1,320 Cr | ₹1,010 Cr | ₹834 Cr | ₹378 Cr |
| Expenses | ₹766 Cr | ₹739 Cr | ₹567 Cr | ₹449 Cr | ₹206 Cr |
| Operating Profit (Excl OI) | ₹574 Cr | ₹582 Cr | ₹443 Cr | ₹385 Cr | ₹172 Cr |
| Other Income | ₹46 Cr | ₹92 Cr | ₹14 Cr | ₹18 Cr | ₹0.60 Cr |
| Interest | ₹13 Cr | ₹8.53 Cr | ₹12 Cr | ₹23 Cr | ₹2.79 Cr |
| Depreciation | ₹48 Cr | ₹39 Cr | ₹32 Cr | ₹24 Cr | ₹11 Cr |
| Profit Before Tax | ₹560 Cr | ₹668 Cr | ₹468 Cr | ₹405 Cr | ₹158 Cr |
| Profit After Tax | ₹411 Cr | ₹454 Cr | ₹362 Cr | ₹317 Cr | ₹109 Cr |
| Consolidated Net Profit | ₹411 Cr | ₹454 Cr | ₹362 Cr | ₹317 Cr | ₹109 Cr |
| Earnings Per Share (Rs) | ₹11.80 | ₹16.16 | ₹17.83 | ₹14.23 | ₹24.91 |
| PAT Margin (%) | 28.56 | 30.66 | 34.35 | 35.89 | 38.02 |
| ROE(%) | 15.87 | 25.21 | 33.52 | 35.78 | 44.58 |
| ROCE(%) | 21.22 | 33.41 | 45.92 | 40.76 | 50.21 |
| Total Debt/Equity(x) | 0.02 | 0.04 | 0.06 | 0.12 | 0.22 |
Key Financials |
||
| Market Cap | : | ₹ 25,817.7 Cr |
| Revenue (TTM) | : | ₹ 961.2 Cr |
| Net Profit(TTM) | : | ₹ 242.9 Cr |
| EPS (TTM) | : | ₹ 9.5 |
| P/E (TTM) | : | 106.3 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| SUVEN PHARMACEUTICALS | -2.2% | -10.7% | 43.1% |
| SUN PHARMACEUTICAL INDUSTRIES | -5.3% | -7.8% | 24.1% |
| CIPLA | -1.9% | -6.9% | 3.6% |
| DR REDDYS LABORATORIES | -8.3% | -14.9% | 0.8% |
| ZYDUS LIFESCIENCES | -5.7% | -4% | 23.6% |
| DIVIS LABORATORIES | -3.9% | -7.9% | 51% |
| MANKIND PHARMA | -5.9% | -14% | 21% |
| TORRENT PHARMACEUTICALS | 2.9% | -0% | 34% |
| LUPIN | -3.8% | -12.1% | 39.2% |
SUVEN PHARMACEUTICALS Revenues
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | 1.52 % |
| 5 Yr CAGR | 37.24 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2024 | ₹1,340 Cr | 1.52 | |
| Mar2023 | ₹1,320 Cr | 30.75 | |
| Mar2022 | ₹1,010 Cr | 21.10 | |
| Mar2021 | ₹834 Cr | 120.68 | |
| Mar2020 | ₹378 Cr | - | |
SUVEN PHARMACEUTICALS Operating Profit
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -1.30 % |
| 5 Yr CAGR | 35.26 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2024 | ₹574 Cr | -1.30 | |
| Mar2023 | ₹582 Cr | 31.31 | |
| Mar2022 | ₹443 Cr | 15.14 | |
| Mar2021 | ₹385 Cr | 124.28 | |
| Mar2020 | ₹172 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -2.77 % |
| 5 Yr CAGR | -1.44 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2024 | 42.84% | -2.77 | |
| Mar2023 | 44.06% | 0.43 | |
| Mar2022 | 43.87% | -4.94 | |
| Mar2021 | 46.15% | 1.65 | |
| Mar2020 | 45.4% | - | |
SUVEN PHARMACEUTICALS Profit After Tax
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -9.37 % |
| 5 Yr CAGR | 39.29 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2024 | ₹411 Cr | -9.37 | |
| Mar2023 | ₹454 Cr | 25.24 | |
| Mar2022 | ₹362 Cr | 14.30 | |
| Mar2021 | ₹317 Cr | 190.10 | |
| Mar2020 | ₹109 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -6.85 % |
| 5 Yr CAGR | -6.90 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2024 | 28.56 % | -6.85 | |
| Mar2023 | 30.66 % | -10.74 | |
| Mar2022 | 34.35 % | -4.29 | |
| Mar2021 | 35.89 % | -5.60 | |
| Mar2020 | 38.02 % | - | |
SUVEN PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -26.98 % |
| 5 Yr CAGR | -17.04 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2024 | ₹12 | -26.98 | |
| Mar2023 | ₹16 | -9.37 | |
| Mar2022 | ₹18 | 25.30 | |
| Mar2021 | ₹14 | -42.87 | |
| Mar2020 | ₹25 | - | |
SUVEN PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 543064|NSE : SUVENPHAR]
| Y-o-Y | -36.49 % |
| 5 Yr CAGR | -19.37 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2024 | 21.22% | -36.49 | |
| Mar2023 | 33.41% | -27.24 | |
| Mar2022 | 45.92% | 12.66 | |
| Mar2021 | 40.76% | -18.82 | |
| Mar2020 | 50.21% | - | |
SUVEN PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹1,014.1 |
| Current MarketCap | : | ₹ 25,817.7 Cr |
| Updated EOD on | : | Jan 29,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| SUVEN PHARMACEUTICALS | -2.2% |
-10.7% |
43.1% |
| SENSEX | 0.2% |
-2.2% |
7.7% |
SUVEN PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| S&P BSE ALLCAP | -0.3% | -3.5% | 35.8% |
| S&P BSE 500 | -0.6% | -5% | 8.7% |
| S&P BSE 400 MIDSMALLCAP | -1.8% | -9.2% | 10.4% |
| S&P BSE HEALTHCARE | -3.4% | -8.9% | 23.7% |
| S&P BSE 250 SMALLCAP | -3.5% | -10.9% | 6.9% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | -0.7% | -5% | 9.2% |
| NIFTY500 MULTICAP 50:25:25 | -1.3% | -6.4% | 9.5% |
| NIFTY MID SMALL400 | -2.1% | -9.1% | 10.1% |
| NIFTY SMALLCAP250 | -3.8% | -11.5% | 7.9% |
You may also like the below Video Courses
FAQ about SUVEN PHARMACEUTICALS Financials
How the annual revenues of SUVEN PHARMACEUTICALS have changed ?
The Revenues of SUVEN PHARMACEUTICALS have increased by 1.52% YoY .
How the Earnings per Share (EPS) of SUVEN PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of SUVEN PHARMACEUTICALS has decreased by -26.98 % YoY .
Check out Intrinsic Value of Peers of SUVEN PHARMACEUTICALS
Compare Stock Analytics of Peers of SUVEN PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs
